FRONTIER IP GROUP PLC | RNS Reach Story | ||
| Go to market news section | ||
|
RNS Reach
AIM: FIPP
20 January 2020
Frontier IP Group plc
('Frontier IP' or the 'Group')
Portfolio news - The Vaccine Group raises £680,000 to accelerate development of novel vaccine technology
Frontier IP, a specialist in commercialising university intellectual property,today announces that portfolio company The Vaccine Group Limited ('the Company' or 'TVG') has raised £680,000 through its first equity funding round.
The proceeds will be used to accelerate development and expand the range of its novel animal vaccine technology. Targeted diseases currently fall into two broad areas: zoonotic diseases, such as Ebola, bird flus and SARs, that jump from animals to animals, including humans; and diseases, such as African swine fever and bovine tuberculosis, which impact economically important livestock. The division between the two varies around the world: bovine tuberculosis is a direct human health threat in many lower and middle countries ('LMICs').
The fundraising values the University of Plymouth spin out at £9.5 million, with Frontier IP's 17 per cent equity stake valued at £1.6 million. This value was reflected in Frontier IP's results at 30 June 2019, announced on 6 November 2019.
TVG's vaccines are based on benign forms of herpesviruses, a group of viruses that are found in all animals, including humans. They are created by inserting a non-infectious region of DNA from the pathogen being targeted into the herpesvirus. This vaccine then stimulates an immune response against the disease when delivered into the animal.
The UK, US and Chinese governments have provided grant funding of more than £9 million to programmes involving TVG. They include projects to tackle:
· Ebola and Lassa fever, funded by the US Department of Defense
· Streptococcus suis, an emerging zoonotic disease in pigs that can be fatal to humans, funded by the UK Department of Health and Social Care and the Chinese government; and
· Bovine mastitis, funded by the global bacterial vaccine network Bactivac.
The Company is also developing vaccines to combat:
· African Swine Fever Virus, a disease currently having a devastating impact on the swine herd in many parts of the world, particularly China; and
· Bovine tuberculosis, seen as a major animal health threat in the UK and to human health in LMICs.
TVG Founder and Chief Scientific Officer, Associate Professor Dr Michael Jarvis, said: 'This initial round of equity funding provides an exciting opportunity to apply this novel vaccine platform towards additional livestock pathogens and deadly zoonotic diseases in humans. Given the much shorter time to market, vaccines designed to interrupt emergence of zoonotic diseases in animals before they spread to humans is becoming regarded as a quicker and more cost-effective way to protect human health.'Frontier IP Chief Executive Officer, Neil Crabb, said: 'TVG's novel technology has huge potential to address some of the most pressing global health challenges we are facing today. The World Health Organisation has repeatedly warned about the pandemic threat from zoonotic diseases. Vaccines also have a critical role to play in protecting people from antibiotic resistant bacteria. We're delighted the Company has successfully completed its first funding round and would like to thank investors for their support.'
ENQUIRIES
Frontier IP Group plc | www.frontierip.co.uk |
Neil Crabb, Chief Executive Andrew Johnson, Communications & Investor Relations | T: 020 7332 2338 M: 07464 546 025 |
Allenby Capital Limited (Nominated Adviser) | T: 0203 328 5656 |
Nick Athanas / Nicholas Chambers |
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
ABOUT THE UNIVERSITY OF PLYMOUTH
The University of Plymouth is renowned for high quality, internationally-leading education, research and innovation.
With a mission to Advance Knowledge and Transform Lives, Plymouth is a *top 50 research university with clusters of world class research across a wide range of disciplines including marine science and engineering, medicine, robotics and psychology. A three-time winner of the Queen's Anniversary Prize for Higher and Further Education, the University of Plymouth continues to grow in stature and reputation.
It has a strong track record for teaching and learning excellence and has one of the highest numbers of National Teaching Fellows of any UK university. With over 19,000 students, and a further 9,500 studying for a Plymouth degree at partner institutions in the UK and around the world, and over 130,000 alumni pursuing their chosen careers globally, it has a growing global presence.http://www.plymouth.ac.uk
*Research Fortnight Research Power League Table 2014.
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| ©2014London Stock Exchange plc. All rights reserved |
Portfolio news - The Vaccine Group raises £680,000 - RNS
Attachments
- Original document
- Permalink
Disclaimer
Frontier IP Group plc published this content on 20 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2020 07:03:03 UTC
